Cybin (HELP) Accumulated Expenses (2021 - 2026)
Cybin's (HELP) quarterly Accumulated Expenses came in at $19.4 million in Q1 2026, up 29.82% YoY from $14.9 million in Q1 2025, and up 19.77% on a QoQ basis from $16.2 million in Q4 2025.
Cybin (HELP) Accumulated Expenses (2021 - 2026) Analysis & Trends
Cybin (HELP) has 6 years of Accumulated Expenses data on file, last reported at $19.4 million in Q1 2026.
- Quarterly Accumulated Expenses rose 29.82% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 29.82% YoY) and the FY2026 annual result came in at $19.4 million, up 30.05% from the prior year.
- Accumulated Expenses climbed to $19.4 million in Q1 2026, from $16.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $19.4 million in Q1 2026 to a low of $3.2 million in Q4 2022.
- A 5-year average of $8.5 million and a median of $6.7 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses sank 47.95% — and 2025, when it surged 151.77%.
- Tracing HELP's Accumulated Expenses over 5 years: stood at $3.2 million in 2022, then jumped by 85.7% to $6.0 million in 2023, then surged by 59.36% to $9.5 million in 2024, then soared by 69.85% to $16.2 million in 2025, then climbed by 19.77% to $19.4 million in 2026.
- The last three Accumulated Expenses figures came in at $19.4 million (Q1 2026), $16.2 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.38 Mn |
| Dec 31, 2025 | 16.18 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Mar 31, 2025 | 14.93 Mn |
| Dec 31, 2024 | 9.53 Mn |
| Sep 30, 2024 | 5.31 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 7.28 Mn |
| Dec 31, 2023 | 5.98 Mn |
| Sep 30, 2023 | 6.89 Mn |
| Jun 30, 2023 | 6.47 Mn |
| Feb 28, 2023 | 3.34 Mn |
| Dec 31, 2022 | 3.22 Mn |
| Sep 30, 2022 | 3.74 Mn |
| Dec 31, 2021 | 2.42 Mn |
| Sep 30, 2021 | 2.09 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 2.21 Mn |